questionsmedicales.fr
Caractéristiques de la population
Facteurs socioéconomiques
Classe sociale
Mobilité sociale
Mobilité sociale : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Mobilité sociale : Questions médicales les plus fréquentes",
"headline": "Mobilité sociale : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Mobilité sociale : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-08",
"dateModified": "2025-04-04",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Mobilité sociale"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Classe sociale",
"url": "https://questionsmedicales.fr/mesh/D012923",
"about": {
"@type": "MedicalCondition",
"name": "Classe sociale",
"code": {
"@type": "MedicalCode",
"code": "D012923",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N01.824.782"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Mobilité sociale",
"alternateName": "Social Mobility",
"code": {
"@type": "MedicalCode",
"code": "D012937",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Richard Breen",
"url": "https://questionsmedicales.fr/author/Richard%20Breen",
"affiliation": {
"@type": "Organization",
"name": "Nuffield College, University of Oxford, Oxford, UK."
}
},
{
"@type": "Person",
"name": "Jung In",
"url": "https://questionsmedicales.fr/author/Jung%20In",
"affiliation": {
"@type": "Organization",
"name": "Nuffield College, University of Oxford, Oxford, UK."
}
},
{
"@type": "Person",
"name": "Adam Vanzella-Yang",
"url": "https://questionsmedicales.fr/author/Adam%20Vanzella-Yang",
"affiliation": {
"@type": "Organization",
"name": "School of Public Health and Sainte-Justine Hospital Research Centre, University of Montreal, Montreal, QC, Canada. adam.vanzella@umontreal.ca."
}
},
{
"@type": "Person",
"name": "Gerry Veenstra",
"url": "https://questionsmedicales.fr/author/Gerry%20Veenstra",
"affiliation": {
"@type": "Organization",
"name": "Department of Sociology, University of British Columbia, Vancouver, BC, Canada."
}
},
{
"@type": "Person",
"name": "Alexi Gugushvili",
"url": "https://questionsmedicales.fr/author/Alexi%20Gugushvili",
"affiliation": {
"@type": "Organization",
"name": "Department of Sociology and Human Geography, University of Oslo, Oslo, Norway."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis.",
"datePublished": "2024-10-31",
"url": "https://questionsmedicales.fr/article/39482761",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13075-024-03418-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.",
"datePublished": "2023-06-15",
"url": "https://questionsmedicales.fr/article/37098795",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/art.42510"
}
},
{
"@type": "ScholarlyArticle",
"name": "A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis.",
"datePublished": "2023-05-15",
"url": "https://questionsmedicales.fr/article/36787101",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/art.42477"
}
},
{
"@type": "ScholarlyArticle",
"name": "Disturbed Complement Receptor Expression Pattern of B Cells Is Enhanced by Toll-like Receptor CD180 Ligation in Diffuse Cutaneous Systemic Sclerosis.",
"datePublished": "2024-08-26",
"url": "https://questionsmedicales.fr/article/39273179",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms25179230"
}
},
{
"@type": "ScholarlyArticle",
"name": "Purtscher-Like Retinopathy Induced by Diffuse Cutaneous Systemic Scleroderma.",
"datePublished": "2023-11-09",
"url": "https://questionsmedicales.fr/article/37950491",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1093/qjmed/hcad255"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Caractéristiques de la population",
"item": "https://questionsmedicales.fr/mesh/D011154"
},
{
"@type": "ListItem",
"position": 3,
"name": "Facteurs socioéconomiques",
"item": "https://questionsmedicales.fr/mesh/D012959"
},
{
"@type": "ListItem",
"position": 4,
"name": "Classe sociale",
"item": "https://questionsmedicales.fr/mesh/D012923"
},
{
"@type": "ListItem",
"position": 5,
"name": "Mobilité sociale",
"item": "https://questionsmedicales.fr/mesh/D012937"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Mobilité sociale - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Mobilité sociale",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Mobilité sociale",
"description": "Comment évaluer la mobilité sociale d'un individu ?\nQuels outils mesurent la mobilité sociale ?\nQuels indicateurs sont utilisés pour le diagnostic ?\nLa mobilité sociale est-elle mesurable ?\nQuels facteurs influencent le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D012937?mesh_terms=Scleroderma,+Diffuse&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Mobilité sociale",
"description": "Quels symptômes indiquent une faible mobilité sociale ?\nComment la mobilité sociale affecte-t-elle la santé mentale ?\nQuels signes montrent une amélioration de la mobilité sociale ?\nLa mobilité sociale impacte-t-elle le bien-être ?\nQuels effets la mobilité sociale a-t-elle sur les relations ?",
"url": "https://questionsmedicales.fr/mesh/D012937?mesh_terms=Scleroderma,+Diffuse&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Mobilité sociale",
"description": "Comment prévenir la stagnation sociale ?\nQuels rôles jouent les familles dans la mobilité ?\nComment les communautés peuvent-elles aider ?\nQuels impacts des politiques éducatives sur la mobilité ?\nComment les réseaux sociaux influencent-ils la mobilité ?",
"url": "https://questionsmedicales.fr/mesh/D012937?mesh_terms=Scleroderma,+Diffuse&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Mobilité sociale",
"description": "Quels traitements favorisent la mobilité sociale ?\nComment les politiques publiques influencent-elles la mobilité ?\nQuels programmes soutiennent la mobilité sociale ?\nComment la formation professionnelle aide-t-elle ?\nQuels rôles jouent les ONG dans la mobilité sociale ?",
"url": "https://questionsmedicales.fr/mesh/D012937?mesh_terms=Scleroderma,+Diffuse&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Mobilité sociale",
"description": "Quelles complications peuvent résulter d'une faible mobilité ?\nComment la faible mobilité affecte-t-elle la santé ?\nQuels effets sur les générations futures ?\nComment la mobilité sociale impacte-t-elle l'économie ?\nQuels risques sociaux sont associés à la stagnation ?",
"url": "https://questionsmedicales.fr/mesh/D012937?mesh_terms=Scleroderma,+Diffuse&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Mobilité sociale",
"description": "Quels facteurs augmentent le risque de faible mobilité ?\nComment l'environnement familial influence-t-il la mobilité ?\nQuel rôle joue l'éducation dans la mobilité ?\nComment les politiques publiques affectent-elles la mobilité ?\nQuels impacts des discriminations sur la mobilité ?",
"url": "https://questionsmedicales.fr/mesh/D012937?mesh_terms=Scleroderma,+Diffuse&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer la mobilité sociale d'un individu ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "On évalue la mobilité sociale par des indicateurs comme le revenu, l'éducation et la profession."
}
},
{
"@type": "Question",
"name": "Quels outils mesurent la mobilité sociale ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des enquêtes et des études longitudinales sont souvent utilisées pour mesurer la mobilité sociale."
}
},
{
"@type": "Question",
"name": "Quels indicateurs sont utilisés pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les indicateurs incluent le niveau d'éducation, le statut professionnel et le revenu familial."
}
},
{
"@type": "Question",
"name": "La mobilité sociale est-elle mesurable ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est mesurable à travers des indices de mobilité intergénérationnelle et intragénérationnelle."
}
},
{
"@type": "Question",
"name": "Quels facteurs influencent le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'origine socio-économique, l'accès à l'éducation et les politiques publiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une faible mobilité sociale ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes incluent le stress financier, l'isolement social et le manque d'opportunités."
}
},
{
"@type": "Question",
"name": "Comment la mobilité sociale affecte-t-elle la santé mentale ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une faible mobilité sociale peut entraîner des troubles mentaux comme l'anxiété et la dépression."
}
},
{
"@type": "Question",
"name": "Quels signes montrent une amélioration de la mobilité sociale ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes incluent une meilleure éducation, un emploi stable et une augmentation des revenus."
}
},
{
"@type": "Question",
"name": "La mobilité sociale impacte-t-elle le bien-être ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une mobilité sociale positive est souvent associée à un meilleur bien-être général."
}
},
{
"@type": "Question",
"name": "Quels effets la mobilité sociale a-t-elle sur les relations ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut influencer les relations interpersonnelles, souvent en élargissant le réseau social."
}
},
{
"@type": "Question",
"name": "Comment prévenir la stagnation sociale ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Encourager l'éducation continue et l'accès à des opportunités d'emploi est essentiel."
}
},
{
"@type": "Question",
"name": "Quels rôles jouent les familles dans la mobilité ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les familles soutiennent l'éducation et les aspirations professionnelles, influençant la mobilité."
}
},
{
"@type": "Question",
"name": "Comment les communautés peuvent-elles aider ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les communautés peuvent offrir des programmes de soutien et des ressources pour l'éducation."
}
},
{
"@type": "Question",
"name": "Quels impacts des politiques éducatives sur la mobilité ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des politiques éducatives inclusives favorisent l'égalité des chances et la mobilité sociale."
}
},
{
"@type": "Question",
"name": "Comment les réseaux sociaux influencent-ils la mobilité ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les réseaux sociaux peuvent offrir des opportunités et des connexions professionnelles importantes."
}
},
{
"@type": "Question",
"name": "Quels traitements favorisent la mobilité sociale ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des programmes d'éducation, de formation professionnelle et d'aide financière peuvent aider."
}
},
{
"@type": "Question",
"name": "Comment les politiques publiques influencent-elles la mobilité ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les politiques d'éducation et d'emploi peuvent améliorer l'accès aux opportunités sociales."
}
},
{
"@type": "Question",
"name": "Quels programmes soutiennent la mobilité sociale ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des programmes de mentorat et de bourses d'études sont efficaces pour soutenir la mobilité."
}
},
{
"@type": "Question",
"name": "Comment la formation professionnelle aide-t-elle ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle améliore les compétences et l'employabilité, facilitant ainsi la mobilité sociale."
}
},
{
"@type": "Question",
"name": "Quels rôles jouent les ONG dans la mobilité sociale ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les ONG offrent des ressources et des programmes pour aider les individus à progresser socialement."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent résulter d'une faible mobilité ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une faible mobilité peut entraîner des inégalités économiques et des tensions sociales."
}
},
{
"@type": "Question",
"name": "Comment la faible mobilité affecte-t-elle la santé ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut conduire à des problèmes de santé physique et mentale dus au stress et à l'isolement."
}
},
{
"@type": "Question",
"name": "Quels effets sur les générations futures ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une faible mobilité sociale peut perpétuer la pauvreté et les inégalités entre générations."
}
},
{
"@type": "Question",
"name": "Comment la mobilité sociale impacte-t-elle l'économie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une faible mobilité peut freiner la croissance économique en limitant le potentiel humain."
}
},
{
"@type": "Question",
"name": "Quels risques sociaux sont associés à la stagnation ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La stagnation sociale peut entraîner des conflits, des tensions et une augmentation de la criminalité."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de faible mobilité ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le niveau d'éducation, l'origine socio-économique et l'accès aux ressources."
}
},
{
"@type": "Question",
"name": "Comment l'environnement familial influence-t-il la mobilité ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un environnement familial instable ou défavorable peut limiter les opportunités de mobilité."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'éducation dans la mobilité ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éducation est un facteur clé qui détermine les opportunités d'emploi et de revenu."
}
},
{
"@type": "Question",
"name": "Comment les politiques publiques affectent-elles la mobilité ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des politiques inéquitables peuvent exacerber les inégalités et limiter la mobilité sociale."
}
},
{
"@type": "Question",
"name": "Quels impacts des discriminations sur la mobilité ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les discriminations peuvent restreindre l'accès à l'éducation et à l'emploi, freinant la mobilité."
}
}
]
}
]
}
Patients with diffuse cutaneous systemic sclerosis (dcSSc) frequently show spontaneous improvement of skin fibrosis. Our aim was to examine whether an improvement in skin fibrosis predicts lower likel...
Patients from the European Scleroderma Trials and Research (EUSTAR) cohort with dcSSc, baseline modified Rodnan skin score (mRSS) ≥7, and valid mRSS at 12±3 months follow up were included. Regression/...
Of 1257 included patients, 883 (70.2%) were stable, 282 (22.4%) regressive, and 92 (7.3%) progressive. Regressive patients, adjusted for baseline mRSS, baseline immunosuppression, baseline FVC, and di...
We found that regression of skin fibrosis is associated with a lower probability of lung progression and better survival at follow up. The link between the disease course of skin and lung fibrosis in ...
This phase 3 study was undertaken to investigate the efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in patients with diffuse cutaneous systemic sclerosis (dcSSc)....
A multinational double-blind study was conducted in 365 dcSSc patients who were randomized and dosed 1:1:1 with lenabasum 20 mg, lenabasum 5 mg, or placebo, each twice daily and added to background tr...
The primary end point, the American College of Rheumatology combined response index in dcSSc (CRISS) at week 52 for lenabasum 20 mg twice a day versus placebo, was not met, with CRISS score of 0.888 v...
A benefit of lenabasum in dcSSc was not demonstrated. Most patients were treated with background IST, and treatment with mycophenolate mofetil in particular was associated with better outcomes. These ...
We undertook this study to explore the efficacy, safety, and tolerability of ziritaxestat, a selective autotaxin inhibitor, in patients with early diffuse cutaneous systemic sclerosis (dcSSc)....
NOVESA was a 24-week, multicenter, phase IIa, double-blind, placebo-controlled study. Adults with dcSSc were randomized to oral ziritaxestat 600 mg once daily or matching placebo. The primary efficacy...
Patients were randomized to ziritaxestat (n = 21) or placebo (n = 12). Reduction in MRSS was significantly greater in the ziritaxestat group versus the placebo group (-8.9 versus -6.0 units, respectiv...
Ziritaxestat resulted in significantly greater reduction in MRSS at week 24 than placebo; no new safety signals emerged. Biomarker analysis suggests ziritaxestat may reduce fibrosis. Modulation of the...
Autoantibody production is a hallmark of systemic sclerosis (SSc) and the most extensively studied role of B cells in the pathogenesis of the disease. However, the potential involvement of innate immu...
We report a rare case of Purtscher-like retinopathy related to systemic sclerosis, presented unprecedently an ultra-widefield optical coherence tomography angiography image for this combination, and s...
Keloidal scleroderma is a variant of scleroderma that presents as firm keloidal nodules or plaques. Due to the similarity in morphology and pathology, it is often distinguished from a hypertrophic sca...
Scleroderma is a systemic inflammatory disorder that can compromise the gastrointestinal tract in up to 90% of patients....
The purpose of this work is to characterize esophageal, gastric, and intestinal compromise in patients with scleroderma by means of minimally invasive methods and its association with symptoms and sev...
Patients with systemic sclerosis were recruited according to the criteria of the American College of Rheumatology. The study of digestive involvement was carried out on four consecutive days: esophage...
A total of 30 patients were included, with an average age of 52.7 years and 93% women. Average disease evolution duration was 6.5 years, 70% with limited variety. Rodnan averaged 12 points, being high...
Gastrointestinal involvement in patients with scleroderma is frequent and is observed regardless of the symptoms and clinical characteristics of the latter, except for skin involvement....
Systemic sclerosis is a systemic connective tissue disease whose main pathophysiological mechanism is a progressive fibrosis of internal organs and skin leading to thickening and induration. Blood ves...
[This corrects the article DOI: 10.3389/fimmu.2024.1351675.]....
Immune checkpoint inhibitors (ICI) are the standard of care for various malignancies and have been associated with a wide spectrum of complications that are phenotypically akin to primary autoimmune d...